Lungs Home > Tracleer

You may receive a medication called Tracleer to treat pulmonary arterial hypertension (PAH). This prescription medicine comes as a tablet that is taken twice daily. Dosing guidelines will vary, based on your weight, other medications you are taking, and various other factors. Side effects are possible and include headaches, swelling, and respiratory tract infections.

What Is Tracleer?

Tracleer® (bosentan) is a prescription medication approved to treat pulmonary arterial hypertension (PAH). PAH is high blood pressure in the blood vessels of the lungs. Tracleer can help people with PAH by improving their ability to exercise and by slowing down how quickly their condition gets worse.
(Click Tracleer Uses for more information on this topic, including possible off-label uses.)

Who Makes This Medication?

Tracleer is made by Actelion Pharmaceuticals US, Inc.

How Does Tracleer Work?

Tracleer is an endothelin receptor antagonist. Endothelins are proteins that have a variety of effects in the body, including effects on the heart, blood vessels, lungs, and kidneys. One of the things endothelins do is cause blood vessels to constrict (narrow).
People with PAH have higher-than-normal levels of endothelins in the body. Tracleer works by blocking two endothelin receptors. This helps block the effects of the extra endothelin in people with PAH.

Clinical Effects

Clinical studies have shown that Tracleer can improve exercise ability in people with PAH. For instance, in one study, people who took this drug for 16 weeks were able to walk 36 meters farther (within six minutes), on average. In comparison, those who took a placebo (a "sugar pill" with no active ingredient) walked eight meters less in six minutes.
Tracleer was also shown to slow clinical worsening of PAH in clinical trials. In these studies, people given the drug had less worsening of their condition, which meant they were less likely to have the following things happen:
  • Go the hospital for PAH
  • Stop treatment because their PAH got worse
  • Need intravenous (IV) treatment
  • Death.
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation

Topics & Medications


Related Channels

eMedTV Links
Copyright © 2006-2020 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.